Encompassing the stark differences in persistence and trafficking between hematological and solid malignancies is an interesting phase I clinical trial which used the same ROR1 targeting CAR-T cells in patients with ROR1 positive chronic lymphocytic leukemia (CLL), breast cancer and non-small cell lung cancer. This evidence concerns the gene ROR1 and breast carcinoma.